학술논문
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 edition)
Document Type
article
Author
Yu Yang; Juxian Sun; Mengchao Wu; Wan Yee Lau; Shusen Zheng; Xue-Hao Wang; Xiaoping Chen; Jia Fan; Jiahong Dong; Jianqiang Cai; Minshan Chen; Yongjun Chen; Zhangjun Cheng; Chaoliu Dai; Jianzhen Shan; Cheng-You Du; Chihua Fang; Heping Hu; Zhili Ji; Weidong Jia; Gong Li; Jing Li; Jiangtao Li; Chang Liu; Fubao Liu; Yong Ma; Yilei Mao; Zuoxing Niu; Jie Shen; Jie Shi; Xuetao Shi; Wenjie Song; Hui-Chuan Sun; Guang Tan; Ran Tao; Xiaohu Wang; Tianfu Wen; Liqun Wu; Jinglin Xia; Bang-De Xiang; Maolin Yan; Mingang Ying; Ling Zhang; Xuewen Zhang; Zhao Chong Zeng; Yubao Zhang; Zhiwei Zhang; Jie Zhou; Cuncai Zhou; Jun Zhou; Ledu Zhou; Xinmin Zhou; Ji Zhu; Zhenyu Zhu; Qi Zhang; Qiu Li; Shuqun Cheng
Source
Liver Cancer (2022)
Subject
Language
English
ISSN
2235-1795
1664-5553
1664-5553
Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are firstly diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the “Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)” based on current clinical studies and clinical medication experience for reference in China. Key messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients and potential population for immunotherapy.